MOTS-c and Tesamorelin Together: What Is Known
MOTS-c and Tesamorelin taken together: what each one is, how each is regulated, and what is known about combining them.
Timing, interactions and safety
Evidence for the combination
No studies tested these together (PubMed search: 1 result, 2 Oct 2026).
Side by side
Showing 12 of 13 fields where the two differ. Evidence strength are the same or both unknown.
| Field | MOTS-c | Tesamorelin |
|---|---|---|
| Class | Mitochondrial-derived peptide | GHRH analog |
| Also called | mots | tesa, Egrifta |
| Category | GLP-1 & metabolic | Growth hormone |
| FDA status | PCAC voted 7–5 for 503A (Jul 2026) | FDA approved (Egrifta) |
| PCAC vote, Jul 2026 | PCAC voted 7–5 for the 503A list (Jul 2026); not finalized | Not on the Jul 2026 agenda |
| WADA | Prohibited by WADA (S4.4.1)MOTS-c is named in S4.4.1 (metabolic modulators: AMPK activators), prohibited at all times. | Prohibited by WADA (S2.2.4)Tesamorelin is named as a GHRH analogue in S2.2.4 (growth hormone releasing factors), prohibited at all times. Tesamorelin is also an FDA-approved medicine; an athlete would need a therapeutic use exemption. |
| Anti-doping detection |
|
|
| Half-life | No published half-life foundPubMed search, 11 Oct 2026 | 11 minutessubcutaneous (EGRIFTA WR 1.28 mg) · FDA label (Egrifta WR) |
| Evidence strength | Human RCT evidence, 4 of 4Strongest: Medicine and science in sports and exercise 2025, PMID 40674654 | Human RCT evidence, 4 of 4Strongest: eNeurologicalSci 2026, PMID 42382101 |
| Human studies we summarised | 7 human (4 randomized or controlled) of 15 summarised | 12 human (11 randomized or controlled) of 16 summarised |
| Typical study doses |
|
|
| Vial sizes sold | 5 mg, 10 mg, 20 mg, 40 mg | 2 mg, 5 mg, 10 mg, 20 mg |
| Named in FDA warning letters, 2026 | Not in the letters we track | Yes (24 Aug 2026) |
MOTS-c vs Tesamorelin
Choosing between the two rather than combining them? The comparison lines them up field by field.
Both get discussed for muscle, with very different evidence
In a tesamorelin analysis, skeletal muscle area and density increased among patients with a clinically significant decrease in visceral fat.[18]
MOTS-c's muscle data are from mice and cells: administration lowered plasma myostatin in diet-induced obese mice, and plasma MOTS-c correlated inversely with myostatin in people.[23]
In mice, intermittent MOTS-c treatment 3 times a week, started late in life, increased physical capacity and healthspan.[24]
Studied together? No
A PubMed search on 2 Oct 2026 for MOTS-c with tesamorelin matched 1 record, which is not recorded as a study of the two together.
Calculated from pubmed query ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (tesamorelin[tiab] OR Egrifta[tiab] OR TH9507[tiab] OR "TH-9507"[tiab]); records matched 1; search date 2026-10-02. Formula: records_matched = PubMed count recorded in combinations.json for the query on search_date
A narrative review of peptides in sports medicine says many unapproved peptides show favorable animal results but rigorous human safety data are scarce.[25]
Label cautions and status
The Egrifta label says to discontinue treatment if there is any evidence of recurrent malignancy, and notes that it increases serum IGF-1, a growth factor.[15]
FDA says it has found no human exposure data for MOTS-c drug products.[26]
On WADA's list MOTS-c appears under activators of AMPK, next to AICAR.[3]
WADA's list also covers tesamorelin as a GHRH analogue.[3]
Common questions
Can you take MOTS-c with tesamorelin?
No study in the cached results tested them together, and FDA has identified no human exposure data on MOTS-c drug products.[26]
Does tesamorelin build muscle?
Muscle area and density rose in a secondary analysis, among patients whose visceral fat fell significantly.[18]
Sources
- 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
- 2FDA gives notice that 12 peptides will be removed from Category 2 (nominations withdrawn)FDA · 2026fda.govAccessed 2 Oct 2026
- 3World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 4Development of a mass spectrometry based detection method for the mitochondrion-derived peptide MOTS-c in plasma samples for doping control purposes.Rapid communications in mass spectrometry : RCM · 2019PMID 30394592Accessed 2 Oct 2026
- 5Repeated Heat Stress Modulates the Levels of the Mitokines MOTS-C and FGF21 in Active Men during Calf Muscle Immobilization.Medicine and science in sports and exercise · 2025PMID 40674654Accessed 2 Oct 2026
- 6Circulating levels of MOTS-c in patients with breast cancer treated with metformin.Aging · 2022PMID 36490309Accessed 2 Oct 2026
- 7Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c in Hispanic and Non-Hispanic White breast cancer survivors.Scientific reports · 2021PMID 34413391Accessed 2 Oct 2026
- 8PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) (262 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 9PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (humans[mh] OR human[tiab] OR participants[tiab] OR patients[tiab] OR volunteers[tiab]) (179 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 10PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (randomized controlled trial[pt] OR "clinical trial"[pt] OR "meta-analysis"[pt] OR "systematic review"[pt]) (5 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 11PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (mice[tiab] OR mouse[tiab] OR rat[tiab] OR rats[tiab]) AND (injection[tiab] OR treatment[tiab] OR administration[tiab] OR treated[tiab]) (72 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 12PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (3 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 13An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.Journal of pharmaceutical and biomedical analysis · 2022PMID 35298973Accessed 2 Oct 2026
- 14Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug testing and analysis · 2021PMID 34665524Accessed 2 Oct 2026
- 15EGRIFTA WR (TESAMORELIN) KIT [THERATECHNOLOGIES INC.]FDA label (Egrifta WR), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 16The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment.eNeurologicalSci · 2026PMID 42382101Accessed 2 Oct 2026
- 17Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.The lancet. HIV · 2019PMID 31611038Accessed 2 Oct 2026
- 18The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV.The Journal of frailty & aging · 2019PMID 31237318Accessed 2 Oct 2026
- 19PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (tesamorelin[tiab] OR Egrifta[tiab] OR TH9507[tiab] OR "TH-9507"[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 20Metabolic effects of a growth hormone-releasing factor in patients with HIV.The New England journal of medicine · 2007PMID 18057338Accessed 2 Oct 2026
- 21Advisory committee backs 6 of 7 peptides for the 503A listNCPA · 2026ncpa.org
- 22PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab] OR CB4211[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (20 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 23MOTS-c reduces myostatin and muscle atrophy signaling.American journal of physiology. Endocrinology and metabolism · 2021PMID 33554779Accessed 2 Oct 2026
- 24MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis.Nature communications · 2021PMID 33473109Accessed 2 Oct 2026
- 25Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.Sports medicine (Auckland, N.Z.) · 2026PMID 41966639Accessed 11 Oct 2026
- 26Official web pageOfficial web page · web page
Found an error? Report a correction.